PS BLUE WHITE PS GREY WHITE BEACH H&S PMS 413

GUIDANCE (TOTAL COMPANY PRO FORMA) 3 $100 $107 Guidance Pro Forma $0.33 $0.42 Guidance Pro Forma Adjusted EBITDA Adjusted EPS (in millions) $200 $293 Guidance Actual Free Cash Flow (in millions) FY 2022 VS. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi en t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 29 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 31 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .4 B ILL ION US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 32 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 33 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 34 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

GUIDANCE (TOTAL COMPANY PRO FORMA) 7 $100 $107 Guidance Pro Forma $0.33 $0.42 Guidance Pro Forma Adjusted EBITDA Adjusted EPS (in millions) $200 $293 Guidance Actual Free Cash Flow (in millions) FY 2022 VS. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 31 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi en t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 32 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E RA W M AT ER IA L OVE RV IE W 34 RAW MATERIAL 2022 ANNUAL PURCHASES Performance Additives 16% Pigments 12% TiO2 11% Dyestuffs 2% Polyethylene 12% Nylon 6% Polypropylene 6% Styrenic Block Copolymer 5% Other Raw Materials 30% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials Excludes Avient Protective Materials SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 36 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .4 B ILL ION US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 37 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 38 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 39

FISCHBACH, Luxembourg – PolyOne Corporation today announced that advanced, halogen-free material solutions are helping Schneider Electric to engineer better product performance, improve efficiency and strengthen its globally recognized sustainability strategy. For more information, visit https://www.se.com/ww/en/.  

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi en t A vi en t (E xc l. D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 24 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 3 4 3 3 4 4 4 5 5 5 5 7 7 8 23 A vi en t A vi en t (E xc l. D is t. ) K W R R P M P P G A V Y F U L G C P F M C H X L IF F F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of March 12, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.

The non-GAAP financial measures include: Adjusted Earnings Per Share, Free Cash Flow, Net Debt/Adjusted EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin. Maintain asset-light, 80% free cash flow conversion profile and be valued as a specialty formulator 5. Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 27 79 89 83 83 78 75 90 81 76 72 68 63 53 11 A vi en t K W R F U L P P G A V Y R P M F M C C E E C L A S H H X L H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTIPLE EXPANSION Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $37.07.

D is t. ) R P M K W R P P G F U L G C P F M C IF F H X L H U N F O E E M N E C L S C L K R A A S H C E G R A A LB As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Median: 3% Median: 5% Capex / Revenue 2021E (%) Source: Capital IQ market data as of August 24, 2020 AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 83 86 85 84 80 56 89 83 82 82 78 76 76 75 71 70 68 63 61 58 14 A vi en t K W R R P M P P G F U L G C P F M C IF F U N V R B N R H X L E C L E M N F O E A S H C E G R A K R A H U N S C L A L B Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Source: Capital IQ market data as of August 24, 2020 Median: 84% Median: 75% HIGH FREE CASH FLOW CONVERSION 3.1x 2.6x 0.5x 1.9x 2.8x 3.1x 4.5x -0.1x 1.8x 1.9x 2.2x 2.3x 2.4x 2.9x 3.0x 3.0x 3.2x 3.4x 3.4x 3.8x 3.9x 4.8x A vi en t ( 20 P F ) A vi en t ( 21 E ) G C P P P G R P M K W R F U L S C L B N R H U N E C L C E F M C A S H H X L E M N G R A A L B IF F U N V R K R A F O E Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA.

TEMPERATURE, MPa Temperature (C) Fl ex ur al S tr en gt h (M Pa ) Fl ex ur al M od ul us (G Pa ) 20 25 30 35 40 Glass/Epoxy High Temp Glass/Vinyl ester 1409040-10-60 0 300 600 900 1200 1500 Glass/Epoxy High Temp Epoxy/Glass Glass/Vinyl Ester 1901409040-10-60 200 400 600 800 1000 1200 14801280108088068048028080 FLEXURAL MODULUS VS. Increasing the free length reduces stiffness and vice versa. Deflection from the neutral axis must not exceed the free length ÷8 for maximum service life.

Maintain asset-light, 80% free cash flow conversion profile and be valued as a specialty formulator 5. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 37 79 89 83 81 76 73 90 82 77 76 74 70 58 22 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of May 31, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $36.50. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 38 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.6 13.2 13.0 12.8 11.3 8.6 17.9 16.8 10.7 8.8 8.8 8.7 7.5 6.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t (2 02 3) K W R P P G R P M A V Y F U L E C L H X L F M C S C L C E A S H E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.